All lobbying filings

AVENUE SOLUTIONS

Lobbying for GENENTECH USA, INC. · Biotechnology

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 2

S 891
Bipartisan Health Care Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Lobbying activity 2

Medicare/Medicaid

Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; Medicare reimbursement for biosimilars

Health Issues

Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues related to 340b drug pricing program; S. 891, Bipartisan Health Care Act H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.